mercredi 7 décembre 2016

Onc Actu du 7 décembre 2016

1. Biologie

Precision Oncology: Epigenetic Patterns Predict Glioblastoma Outcomes [NIH Director's Blog]

Immune-Cell Traps May Aid Cancer Metastasis [NIH]

4.10 Dép., diag. & prono. - Poumon

Could a smartphone app help doctors diagnose lung cancer? [Cancer Research UK]

5. Traitements

How mice are helping personalize cancer treatment [STAT]

5.12.2 Immunothérapies - CAR-T

Juno Needs to Back a Different CAR-T Horse [Bloomberg]

5.13 WCLC

Opdivo (nivolumab) Alone or Combined With Yervoy (ipilimumab) Shows Encouraging Response and Survival Rates in Recurrent Small Cell Lung Cancer, From Phase 1/2 Study CheckMate -032 [BMS]

New Lung Cancer Tumor Staging Manual to Shape Lung Cancer Clinical Treatment [IASLC]

Novartis announces Zykadia® first-line study results showing 16.6 month progression-free survival in patients with ALK+ advanced NSCLC [Novartis]

Updated KEYTRUDA® (pembrolizumab) Data in Small Cell Lung Cancer and Mesothelioma Presented at 17th World Conference on Lung Cancer [Merck]

In a rare blockbuster performance for AstraZeneca, Tagrisso comes through on lung cancer PhIII [EndPoints]

KEYTRUDA® (pembrolizumab) Demonstrated Improved Health-Related Quality of Life Compared to Chemotherapy in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) [Merck]

Novartis' drug tops chemotherapy in untreated lung cancer patients [Reuters]

5.2.1 Pharma - Partenariats

AbbVie pens oncology research pacts with academic teams [FierceBiotech]

5.3 Traitements - FDA, EMA, NICE...

EU clears Bristol-Myers immunotherapy drug for blood cancer [Reuters]

5.3.4 Traitements - AMM (FDA, EMA)

FDA Approves Genentech’s Avastin® (Bevacizumab) Plus Chemotherapy for a Specific Type of Advanced Ovarian Cancer [Genentech]

5.8 ASH

ASH Roundup: CAR-T Shuffle, Hemophilia Updates, Checkpoint Progress & More [Xconomy]

5.8.1 ASH - Communiqués

Kite Pharma Presents Results of Multi-Center Pivotal ZUMA-1 Trial of Axicabtagene Ciloleucel (KTE-C19) in Aggressive Non-Hodgkin Lymphoma as Late-Breaking Abstract at Annual Meeting of American Society of Hematology [Kite]

Juno Therapeutics Highlights Progress with Best-in-Class Strategy in B-Cell Malignancies at ASH [Juno]

ARIAD Announces Data Presentations at American Society of Hematology Meeting [Ariad]

Phase III Studies Present Additional Evidence for REVLIMID® (lenalidomide) as Maintenance Therapy in Multiple Myeloma [Celgene]

New Analysis Shows People with Cancer Who Received XARELTO® (rivaroxaban) for Blood Clots Had Fewer ER Visits and Lower Healthcare Costs than Those Given Standard Treatment [Johnson & Johnson]

Late-Breaking Ibrutinib (IMBRUVICA®) Data Show Complete or Partial Response in Two-Thirds of Patients with Chronic Graft-Versus-Host-Disease, a Frequent and Potentially Life-Threatening Complication of Stem Cell Transplant [AbbVie]

5.8.4 ASH - CAR T

At Late-Night ASH Talk, Juno Execs Look Beyond Stalled “Rocket” Trial [Xconomy]

First Multicenter Trial Finds CAR T-Cell Immunotherapy Effective, Feasible for Hard-to-Treat Lymphoma [ASH]

5.8.5 ASH - Myélome multiple

Additions to Standard Multiple Myeloma Therapy Do Not Appear to Yield Additional Benefit [ASH]

5.8.6 ASH - Leucémies

IKZF1 Gene Mutations Found to Increase Hereditary Risk for Acute Lymphocytic Leukemia in Children [ASH]

6. Lutte contre les cancers

China is narrowing the U.S. lead in cancer research [FierceBiotech]

Reform regulations to make pet clinical trials easier [Nature]

6.10.1 Politiques (USA)

ASCO Applauds House for Passing the STAR Act and Supporting Children with Cancer [ASCO]

With media watchdogs on the sidelines, pharma-funded advocacy groups pushed Cures Act to the finish line [HealthNewsReview]

The FDA Is Not Hindering Medical Progress [Pacific Standard]

New medical research bill aims to help early-career scientists [Science]

6.11 Patients

Woman gives birth to own grandson as surrogate for her cancer survivor daughter [The Telegraph]